Hussain R, Ghoumari AM, Bielecki B, Steibel J, Boehm N, Liere P, Macklin WB, Kumar N, Habert R, Mhaouty-Kodja S, Tronche F, Sitruk-Ware R, Schumacher M, Ghandour MS. Brain. 2013 Jan;136(Pt 1):132-46.
We demonstrated (in collaboration with INSERM U788) that testosterone and its analogs might constitute an efficient treatment against myelin diseases such as multiple sclerosis. We showed that myelin repair can be induced in mice suffering from chronic demyelination by testosterone and a synthetic analog, through the regeneration of oligodendrocytes, the myelin forming cells in the central nervous system.
Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir H, Cavillon G, Rogemond V, Casey R, Frangoulis B, De Sèze J, Vukusic S, Honnorat J, Confavreux C; NOMADMUS Study Group. Neurology. 2013 Jun 11;80(24):2194-200.
This large collaborative study demonstrates that several assays for AQP-4 dosage (especially CBA-M23) are more sensitive and allow to increase the sensitivity of NMO diagnosis.
Kremer S, Lamy J, Magnus A, Oesterle H, Jeantroux J, Trunet S, Armspach JP, Dietemann JL, de Sèze J. Neurology. 2013 Jul 16;81(3):206-10
This study evaluates the interest of a new gadolinium contrast agent in the evaluation of MS.
Yassine N, Lazaris A, Dorner-Ciossek C, Després O, Meyer L, Maitre M, Mensah-Nyagan AG, Cassel JC, Mathis C. Neurobiol Aging. 2013 Mar;34(3):716-30.
This paper shows that the object recognition test and the Barnes maze are extremely useful to assess spatial memory deficits and to evaluate cognitive therapies in tg2576 mice and other mouse models bred on a background susceptible to visual impairment.
Chanson JB, Echaniz-Laguna A, Blanc F, Lacour A, Ballonzoli L, Kremer S, Namer IJ, Lannes B, Tranchant C, Vermersch P, de Seze J. J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):392-7.
This study demonstrates that CMT1-a is not restrictive to peripheral nervous system and may induce central nervous system abnormalities.
Klein C, Patte-Mensah C, Taleb O, Bourguignon JJ, Schmitt M, Bihel F, Maitre M, Mensah-Nyagan AG. Neuropharmacology. 2013 Jul;70:254-60.
This paper shows that a part of the neuroprotective effect of kynurenic acid may depend on its ability to induce the expression and/or activity of the amyloid-degrading enzyme neprylisn in nerve cells.
Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG. PLoS One. 2013 Nov 15;8(11)
This article shows that the prophylactic or corrective treatment with 3α-androstanediol prevents or suppresses PAC-evoked painful symptoms and peripheral nerve dysfunctions in rats. The data suggest that 3α-androstanediol-based therapy may constitute an efficient strategy to explore in humans for the eradication of chemotherapy-induced peripheral neuropathy.
Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takai Y, Collongues N, Banwell B, Fujihara K, de Seze J. Mult Scler. 2013 Oct 7.
This large international collaborative paper demonstrates that brainstem symptoms are frequent in NMO and some of them associated with AQP4 positive antibodies should conducted to the diagnostic of NMO.
Bouyon M, Collongues N, Zéphir H, Ballonzoli L, Jeanjean L, Lebrun C, Chanson J, Blanc F, Fleury M, Outteryck O, Defoort S, Labauge P, Vermersch P, Speeg C, De Seze J. Mult Scler. 2013 Sep;19(10):1320-2.
This study demonstrates the interest of OCT examination in the longitudinal follow-up of NMO.
Meyer L, Boujedaini N, Patte-Mensah C, Mensah-Nyagan AG. Behav Brain Res. 2013 Sep 15;253:90-4.
Our results constitute a solid set of fundamental data directly demonstrating anxiolytic properties of gelsemine. The report also opens new perspectives for the development of safe and effective gelsemine- or Gelsemium-based strategies against pathological anxiety.
Chanson JB, Lamy J, Rousseau F, Blanc F, Collongues N, Fleury M, Armspach JP, Kremer S, de Seze J. Eur J Neurol. 2013 Feb;20(2):361-7.
This study demonstrates that brain atrophy is frequently observed in NMO but focussed on the white matter and not to grey matter.
Sato DK, Lana-Peixoto MA, Fujihara K, de Seze J. Brain Pathol. 2013 Nov;23(6):647-60.
The papers reviewed the evolving clinical spectrum, the updated clinical, MRI, neuro-ophthalmological and laboratory findings, and the current status of treatment in NMOSD.
Créange A, Careyron A; French CIDP study group. J Neurol. 2013 Dec;260(12):3015-22.
This study shows that a set of criteria and a diagnostic strategy are not sufficient to reach a consensus for the diagnosis of atypical CIDP in clinical practice.
de Seze J, Collongues N. Expert Rev Clin Immunol. 2013 Oct;9(10):979-86.
In this study, we detail the moving concept of NMOSD from the recent years and propose some therapeutic strategies that are clearly different compared with multiple sclerosis treatment.